In a study of 1,964 patients with multiple sclerosis (MS) led by researchers at the NYU Langone Multiple Sclerosis Comprehensive Care Center, extending the dose of natalizumab from 4 weeks up to 8 weeks was shown to be well-tolerated ...
Apr 20, 2015
0
9
A commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS specialists NYU Langone Health.
Feb 3, 2018
0
34
Taking the new generation anti-inflammatory drug natalizumab for two years lowers the number of remitting multiple sclerosis patients who experience relapses and progression of disability. This is the main finding of a systematic ...
Oct 5, 2011
0
0
(HealthDay)—The U.S. Food and Drug Administration is investigating the possible association between a rare brain infection and the multiple sclerosis (MS) drug Gilenya (fingolimod), according to a drug safety alert issued ...
Aug 31, 2013
0
0
MS relapses of clinical relevance are known to occur in up to 80 percent of patients within four to seven months of stopping natalizumab. It is also a known fact that pregnancy has a mitigating effect on the disease. To find ...
Feb 4, 2022
0
11
(HealthDay)—Natalizumab may be safe in pediatric multiple sclerosis (MS) patients with highly active disease, according to a small study published online Feb. 18 in JAMA Neurology.
Feb 22, 2013
0
0
Amyloids—clumps of misfolded proteins found in the brains of people with Alzheimer's disease and other neurodegenerative disorders—are the quintessential bad boys of neurobiology. They're thought to muck up the seamless ...
Apr 3, 2013
1
0
A best treatment pathway has been identified for people with multiple sclerosis (MS) whose current medication puts them at risk of a serious brain infection.
Jun 5, 2023
0
27
(HealthDay)—Rituximab has better efficacy and lower discontinuation rates than other disease-modifying treatment (DMT) choices for newly diagnosed relapsing-remitting multiple sclerosis (RRMS), according to a study published ...
Jan 9, 2018
0
3
(HealthDay) -- Drug company researchers say they've determined which multiple sclerosis patients are most vulnerable to developing a rare brain infection while taking a powerful drug called Tysabri (natalizumab).
May 17, 2012
0
1
